NICE Rejects Keytruda/Inlyta Combo First-Line In RCC
More Mature Evidence Needed Says Draft Guidance
Executive Summary
The cost-effectiveness of combination therapies for untreated advanced renal cell carcinoma therapies comes under the spotlight as England's HTA body rejects an immunotherapy/kinase inhibitor combination in draft guidance.